Center for Rehabilitation Medicine, Department of Pain Management, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, 330004, China.
Department of Clinical Pharmacy, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China.
Mol Pharm. 2024 Oct 7;21(10):4764-4785. doi: 10.1021/acs.molpharmaceut.3c01104. Epub 2024 Sep 5.
Spinal cord injury (SCI) is a highly disabling neurological disorder. Its pathological process comprises an initial acute injury phase (primary injury) and a secondary injury phase (subsequent chronic injury). Although surgical, drug, and cell therapies have made some progress in treating SCI, there is no exact therapeutic strategy for treating SCI and promoting nerve regeneration due to the complexity of the pathological SCI process. The development of novel drug delivery systems to treat SCI is expected to significantly impact the individualized treatment of SCI due to its unique and excellent properties, such as active targeting and controlled release. In this review, we first describe the pathological progression of the SCI response, including primary and secondary injuries. Next, we provide a concise overview of newly developed nanoplatforms and their potential application in regulating and treating different pathological processes of SCI. Then, we introduce the existing potential problems and future clinical application perspectives of biomedical engineering-based therapies for SCI.
脊髓损伤（SCI）是一种高度致残的神经疾病。其病理过程包括初始的急性损伤阶段（原发性损伤）和继发性损伤阶段（随后的慢性损伤）。尽管手术、药物和细胞治疗在治疗 SCI 方面取得了一些进展，但由于 SCI 病理过程的复杂性，目前还没有确切的治疗 SCI 和促进神经再生的治疗策略。新型药物输送系统的开发有望对 SCI 的个体化治疗产生重大影响，因为其具有主动靶向和控制释放等独特而优异的特性。在这篇综述中，我们首先描述了 SCI 反应的病理进展，包括原发性和继发性损伤。接下来，我们简要概述了新开发的纳米平台及其在调节和治疗 SCI 不同病理过程中的潜在应用。然后，我们介绍了基于生物医学工程的 SCI 治疗方法的现有潜在问题和未来临床应用前景。
